

7 Literaturverzeichnis

1. **American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:** Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* (1992) 20: 864-874
2. **American Society of Clinical Oncology:** Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. *J Clin Oncol* (1994) 12: 2471-2508
3. **Auner HW, Sill H, Mulabecirovic A, Linkesch W and Krause R:** Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. *Ann Hematol* (2002) 81: 374-377
4. **Auner HW, Zebisch A, Ofner P, Sill H, Linkesch W and Krause R:** Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases. *Ann Hematol* (2005) 84: 532-537
5. **Baynes RD, Hamm C, Dansey R et al.:** Bone marrow and peripheral blood hematopoietic stem cell transplantation: Focus on autografting. *Clinical Chemistry* (2000) 46: 1239-1251
6. **Bearman SI, Appelbaum FR, Buckner CD et al.:** Regimen-related toxicity in patients undergoing bone marrow transplantation. *J Clin Oncol* (1988) 6: 1562-1568
7. **Beyer J, Schwella N, Zingsem J et al.:** Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. *J Clin Oncol* (1995) 13: 1328-1335
8. **Bilgrami S, Aslanzadeh J, Feingold JM et al.:** Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. *Bone Marrow Transplant* (1999) 24: 69-74
9. **Bishop MR, Anderson JR, Jackson JD et al.:** High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. *Blood* (1994) 83: 610-616
10. **Bowden RA, Meyers JD:** Infectious complications following marrow transplantation. *Plasma Ther Transfusion Tech* (1985) 6: 285-302
11. **Brugger W, Bross K, Frisch J et al.:** Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating

- factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. *Blood* (1992) 79: 1193-1200
12. **Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R and Kanz L:** Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. *Blood* (1994) 83: 636-640
 13. **Chandrasekar PH, Abraham OC, Klein J et al.:** Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. *Clin Infect Dis* (2001) 32: 546-551
 14. **Cooper BW, Moss TJ, Ross AA, Ybanez J and Lazarus HM:** Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. *J Clin Oncol* (1998) 16: 3509-3517
 15. **Crippa F, Holmberg L, Carter RA et al.:** Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* (2002) 8: 281-289
 16. **D'Hondt V, Guillaume T, Humblet Y et al.:** Tolerance of sequential or simultaneous administration of interleukin-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. *Bone Marrow Transplant* (1994) 13: 261-264
 17. **Darouiche RO, Raad II, Heard SO et al.:** A comparison of two antimicrobial-impregnated central venous catheters. *New Engl J Med* (1999) 340: 1-8
 18. **De Rosa L, Anghel G, Pandolfi A, Riccardi M, Amodeo R and Majolino I:** Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34(+) cell-selected peripheral blood progenitor cell transplantation. *Int J Hematol* (2004) 79: 85-91
 19. **Deeg HJ:** Delayed complications after bone marrow transplantation, in Forman ST, Blume KG, Donnell TE (eds.): *Bone Marrow Transplantation*. Boston, Blackwell Scientific (1994): 538-544
 20. **Deisseroth AB, Zu Z, Claxton D et al.:** Genetic marking shows that Ph⁺ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relaps after autologous bone marrow transplantation in CML. *Blood* (1994) 83: 2068-2076
 21. **Egerer G, Goldschmidt H, Hensel M et al.:** Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. *Bone Marrow Transplant* (2002) 30: 427-431

22. **Elias AD, Ayash L, Anderson KC et al.:** Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. *Blood* (1992) 79: 3036-3044
23. **Frei E, Canellos GP:** Dose: a critical factor in cancer chemotherapy. *Am J Med* (1980) 69: 585-594
24. **Freifeld AG, Pizzo PA, Walsh TJ:** Infections in the cancer patient, in DeVita VT, Hellman S, Rosenberg SA (eds.): *Cancer: Principles & Practice of Oncology*, Fifth Edition, Philadelphia, Lippincott-Raven (1997)
25. **Goldberg MA, Antin JH, Guinan EC and Rapoport JM:** Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. *Blood* (1986) 68: 114-118
26. **Gratwohl A:** Entwicklung der hämatopoetischen Vorläuferzell-Transplantation, in Bartsch HH, Mertelsmann R (Hrsg.): *Knochenmark- und periphere Stammzelltransplantation*. Basel, Karger (1996): 1-7
27. **Gratwohl A, Passweg J, Baldomero H and Hermans J:** Blood and marrow transplantation activity in Europe 1997 (European Group for Blood and Marrow Transplantation [EBMT]). *Bone Marrow Transplant* (1999) 24: 231-245
28. **Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A:** Hematopoietic stem cell transplantation activity in Europe 1999 (European Group for Blood and Marrow Transplantation [EBMT]). *Bone Marrow Transplant* (2001) 27: 899-916
29. **Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J and Urbano-Ispizua A:** Current trends in hematopoietic stem cell transplantation in Europe (European Group for Blood and Marrow Transplantation [EBMT]). *Blood* (2002) 100: 2374-2386
30. **Gratwohl A, Baldomero H, Frauendorfer K and Urbano-Ispizua A:** EBMT activity survey 2004 and changes in disease indication over the past 15 years (Joint Accreditation Committee of ISCT and EBMT). *Bone Marrow Transplant* (2006) 37: 1069-1085
31. **Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A and Niederwieser D:** Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors (Joint Accreditation Committee of ISCT and EBMT). *Bone Marrow Transplant* (2007) 39: 71-87
32. **Haas R, Ehrhardt R, Witt B et al.:** Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. *Bone Marrow Transplant* (1993) 12: 643-649

33. **Haas R, Mohle R, Fruhauf S et al.:** Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. *Blood* (1994) 83: 3787-3794
34. **Hartmann O, Le Corroller AG, Blaise D et al.:** Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs - A randomized, controlled trial. *Ann Intern Med* (1997) 126: 600-607
35. **Hebart H, Einsele H:** Infektiöse Komplikationen nach autologer und allogener Stammzelltransplantation, in Bartsch HH, Mertelsmann R (Hrsg.): Knochenmark- und periphere Stammzelltransplantation. Basel, Karger (1996): 16-24
36. **Herrmann RP, Trent M, Cooney J and Cannell PK:** Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. *Bone Marrow Transplant* (1999) 24: 1213-1217
37. **Herwaldt LA, Hollis RJ, Boyken LD and Pfaller MA:** Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. *Infect Control Hosp Epidemiol* (1992) 13: 86-92
38. **Ho AD, Gluck S, Germond C et al.:** Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. *Leukemia* (1993) 7: 1738-1744
39. **Hohaus S, Goldschmidt H, Ehrhardt R and Haas R:** Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rh-G-CSF. *Exp Hematol* (1993) 21: 508-514
40. **Holmberg LA, Boeckh M, Hooper H et al.:** Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. *Blood* (1999) 94: 4029-4035
41. **Hughes WT, Armstrong D, Bodey GP et al.:** 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever (Infectious Diseases Society of America). *Clin Infect Dis* (1997) 25: 551-573
42. **Ketterer N, Espinouse D, Chomarat M et al.:** Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. *Am J Med* (1999) 106: 191-197
43. **Kirk JL, Greenfield RA, Sleese RB and Epstein RB:** Analysis of early infectious complications after autologous bone marrow transplantation. *Cancer* (1988) 62: 2445-2450

44. **Klumpp TR, Mangan KF, Glenn LD et al.:** Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. *Bone Marrow Transplant* (1993) 12: 337-345
45. **Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C and Aulitzky WE:** Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. *Bone Marrow Transplant* (1997) 19: 143-147
46. **Krüger W, Rüssmann B, Kröger N et al.:** Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single center investigation of 409 cases. *Bone Marrow Transplant* (1999) 23: 589-597
47. **Lange W:** Autologe hämatologische Stammzelltransplantation, in Bartsch HH, Mertelsmann R (Hrsg.): *Knochenmark- und periphere Stammzelltransplantation*. Basel, Karger (1996): 8-15
48. **Lennard AL, Jackson GH:** Stem cell transplantation. *BMJ* (2000) 321: 433-437
49. **Léonard BM, Héту F, Busque L et al.:** Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than on log difference between bone marrow and peripheral blood cell sources. *Blood* (1998) 83: 636-640
50. **Link H, Blumenstengel K, Böhme A et al.:** Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie (Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie). *Dtsch Med Wschr* (1999) 124: 3-8
51. **Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M et al.:** Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe (European Group for Blood and Marrow Transplantation [EBMT]). *Bone Marrow Transplant* (2006) 37: 439-449
52. **Lorenz E, Uphoff D, Reid TR and Shelton E:** Modification of irradiation injury in mice and guinea pigs by bone marrow injections. *J Natl Cancer Inst* (1951) 12: 197-203
53. **Martin S, Voso MT, Hohaus S, Ho AD and Haas R:** The time to hematopoietic reconstitution following high-dose therapy in cancer patients is related to the number of CD34+ cells transplanted, diagnosis and type of conditioning regimen. *Ann Hematol* (1998) 77: Suppl 1, A5
54. **Maschmeyer G, Hertenstein B, Glaß B und Schiel X:** Interventionelle antimikrobielle Therapie febriler Komplikationen nach Hochdosistherapie und autologer Stammzelltransplantation (Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in

- der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie). Dtsch Med Wschr (1999) 124: 9-13
55. **Mathé G, Jammet H, Pendic B et al.:** Transfusions and grafts of homologous bone marrow in humans after accidental high dosage irradiation. Rev Fr Etud Clin Biol (1959) 4: 226-238
 56. **McDonald GB, Hinds MS, Fisher LD et al.:** Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med (1993) 118: 255-267
 57. **Meisenberg BR, Miller WE, McMillan R et al.:** Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol (1997) 15: 11-17
 58. **Meyers JD:** Infection in bone marrow transplant recipients. Am J Med (1986) 81: Suppl 1A, 27-38
 59. **Miyamoto T, Gondo H, Miyoshi J et al.:** Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol (1998) 100: 348-350
 60. **Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF and Bolwell BJ:** Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant (1996) 18: 265-271
 61. **Munker R, Hiller E, Paquette R:** Modern hematology: biology and clinical management. Totowa, Humana Press Inc. (2000)
 62. **Nademanee A, Sniecinski I, Schmidt GM et al.:** High-dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. J Clin Oncol (1994) 12: 2176-2186
 63. **Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD and Armstrong D:** Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant (1996) 18: 355-359
 64. **Offidani M, Corvatta L, Olivieri A et al.:** Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant (1999) 24: 1079-1087
 65. **Pedrazzoli P, Battaglia M, Da Prada GA et al.:** Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplant (1997) 20: 167-169

66. **Pizzo PA, Armstrong D, Bodey GP et al.:** The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel for the Immunocompromised Host Society. *J Infect Dis* (1990) 161: 397-401
67. **Pizzo PA:** Management of fever in patients with cancer and treatment induced neutropenia. *New Engl J Med* (1993) 328: 1323-1332
68. **Reich G, Mapara MY, Reichardt P, Dörken B and Maschmeyer G:** Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. *Bone Marrow Transplant* (2001) 27: 525-529
69. **Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB and Sonis ST:** The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. *Cancer* (1998) 82: 2275-2281
70. **Salazar R, Solá C, Marato P et al.:** Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* (1999) 23: 27-33
71. **Seropian S, Nadkarni R, Jillella AP et al.:** Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. *Bone Marrow Transplant* (1999) 23: 599-605
72. **Sezer O, Eucker J, Lüftner D, Bauhuis C et al.:** Infectious complications in high-dose chemotherapy with autologous peripheral stem cell support. ECC-2 and BICON-7 1998. *Antiinfect. Drugs Chemother.* (1998) 16: Suppl 1, 14
73. **Sezer O, Mergenthaler HG, Eucker J, Lüftner D, Bauhuis C et al.:** Does the course of febrile neutropenia after high-dose chemotherapy differ in patients with malignant lymphomas and solid tumors? ISH-EHA Combined Haematology Congress 1998. *Br J Haematol* (1998) 102: 212
74. **Sezer O, Eucker J, Lüftner D, Bauhuis C et al.:** Does the course of febrile neutropenia after high-dose chemotherapy differ in patients with malignant lymphomas and breast cancer? Annual Congress of the German and the Austrian Societies of Hematology and Oncology 1998. *Ann Hematol* (1998) 77: Suppl II, 197
75. **Sezer O, Illiger HJ, Eucker J, Bauhuis C et al.:** Infectious complications during high dose therapy with autologous blood stem cell transplantation. 4th International Stem Cell

Workshop: High Dose Therapy and Transplantation of Haematopoietic Stem Cells 1999.
Abstractband (1999) Poster #3: 14

76. **Sezer O, Bauhuis C, Metzner B et al.:** Multivariate analysis of factors influencing the rate of documented infections in 500 cycles high-dose chemotherapy with autologous peripheral stem cell transplantation. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie 1999. *Onkologie* (1999) 25 (Suppl 1): 134
77. **Sezer O, Eucker J, Bauhuis C et al.:** Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer after high-dose chemotherapy with autologous peripheral stem cell transplantation. *Ann Hematol* (2000) 79: 627-630
78. **Sezer O, Eucker J, Fuss H, Bauhuis C et al.:** Infectious complications during high dose therapy with autologous peripheral stem cell transplantation. In: *High Dose Therapy and Transplantation of Haematopoietic Stem Cells*. Blackwell (2000): 90-93
79. **Sezer O, Eucker J, Metzner B, Wattad M, Fuss H, Bauhuis C et al.:** Mucositis is associated with increased rate of documented infections and treatment-related mortality after high-dose therapy with autologous peripheral stem-cell transplantation. American Society of Clinical Oncology, 36th Annual Meeting, 2000. *Proc Am Soc Clin Oncol* (2000) 19: 56a
80. **Sezer O, Possinger K, Metzner B et al.:** Optimal CD 34+ cell dose in autologous peripheral stem cell transplantation. *J Clin Oncol* (2000) 18: 3319-3320
81. **Shiobara S, Harada M, Mori T et al.:** Difference in posttransplant recovery of immune reactivity between allogeneic and autologous bone marrow transplantation. *Transplant Proc* (1982) 2: 429-433
82. **Sica S, Di Mario A, Salutari P et al.:** Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. *Am J Hematol* (1994) 46: 18-23
83. **Sutherland HJ, Eaves CJ, Lansdorp PM, Phillips GL and Hogge DE:** Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. *Blood* (1994) 83: 3808-3814
84. **Talmadge JE, Reed E, Ino K et al.:** Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. *Bone Marrow Transplant* (1997) 19: 161-172
85. **Thomas ED, Lochte HL, Lu WC and Ferrebee JW:** Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *N Engl J Med* (1957) 257: 491-496

86. **Toor AA, van Burik JA and Weisdorf DJ:** Infections during mobilizing chemotherapy and following autologous stem cell transplantation. *Bone Marrow Transplant* (2001) 28: 1129-1134
87. **Urbano-Ispizua A, Schmitz N, de Witte T et al.:** Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe (European Group for Blood and Marrow Transplantation [EBMT]). *Bone Marrow Transplant* (2002) 29: 639-646
88. **Weaver CH, Hazelton B, Birch R et al.:** An analysis of engraftment kinetics as a function of the CD₃₄ content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. *Blood* (1995) 86: 3961-3969
89. **Weaver CH, Schwartzberg LS, Hainsworth J et al.:** Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. *Bone Marrow Transplant* (1997) 19: 671-678
90. **Wörmann B:** Hochdosistherapie mit Stammzelltransplantation. *Internist* (1998) 39: 1115-1122
91. **Yeh SP, Chiu CF, Lo WJ et al.:** Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis. *Ann Hematol* (2003) 82: 24-29
92. **Zeller W, Cassens U, Stockschlader M et al.:** Higher dose of G-CSF increases yield of mobilized CD34+ cells. *Blood* (1994) 84 Suppl 1: 106